Prevalence Of High-risk Genotypes Research Articles

HIGH PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS AND HIGH FREQUENCY OF MULTIPLE HPV GENOTYPES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED WOMEN IN INDIA

Groups of 208 human immunodeficiency virus (HIV)-infected women in India were studied for the presence of human papillomavirus with the general SPF10 PCR primer set. Virtually all (98%) women were found positive for human papillomavirus (HPV) DNA. Genotyping by the reverse hybridization line probe assay (HPV-LiPA) revealed a high prevalence of multiple genotypes (78.9% of the cases), with an average of 3.1 genotypes per patient (range, 1 to 10 genotypes). HPV 6 was the most prevalent genotype and was observed in 80 (39.2%) patients, followed by types 51 (31.9%), 11 (26.0%), 18 (24.0%), and 16 (22.5%). Of the genotypes detected, 40.9% were low-risk genotypes. Twenty-two (10.5%) patients showed normal (Pap I) cytology, 149 (71.6%) patients had inflammation (Pap II), and 28 patients (13.4%) had a Pap III score. The prevalence of high-risk genotypes increased with the cytological classification. There were no significant associations between the number of HPV genotypes detected and the cytological classification, HIV viral load, and CD4 count in these patients. In conclusion, the highly sensitive SPF10 LiPA system shows that very high proportions of HIV-infected women in Brazil is infected with HPV and often carry multiple HPV genotypes.
 Key-words: HIV, Human Papillomavirus, Genotypes, Women

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant inter-population pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective.

Prevalence of high risk genotypes of human papillomavirus in anal samples from men who have sex with men with abnormal cytology in Madrid

Prevalence of high risk genotypes of human papillomavirus in anal samples from men who have sex with men with abnormal cytology in Madrid

Human Papilloma virus genotype diversity of anal infection among trans (male to female transvestites, transsexuals or transgender) sex workers in Argentina

Background Reports on the prevalence and genotypes of HPV among trans (male to female transvestites, transsexuals or transgender) sex workers (TSW) are scarce in the literature. Objectives The aim of the study was to determine the infecting HPV genotypes among TSW in Argentina. Study design 119 TSW were recruited. Anal cells were self collected with a cytobrush. HPV DNA detection was carried out by PCR and genotyping was performed by RLB. Results HPV prevalence was 97.4%. 103/111 HPV positive samples were genotyped. High risk genotypes were detected in 82.5%. Two or more coinfecting HPV genotypes were found in 70.9%. One case showed up to 10 different coinfecting types. The number of genotypes was not related to condom usage. Infection rates were similar for HIV positive (100%) and HIV negative (95.8%) participants. However, 18.8% of HIV negative had 4–9 different genotypes, while among HIV positive this percentage raised to 46.2% ( p = 0.006). Prevalence of high risk genotypes and the frequency of each high risk type were similar between HIV positive and HIV negative groups. According to the participants’ answers HIV status showed no association with condom usage. Conclusions The high HPV prevalence, the coinfection with multiple genotypes and the high frequency of high risk genotypes detected, together with a situation of extreme social marginalization, discrimination and stigmatization make this population to be of extreme vulnerability.

Low prevalence of high risk genotypes of human papilloma virus in normal oral mucosa, oral leukoplakia and verrucous carcinoma

Objective. Squamous Cell Carcinoma (SCC) is the most common malignancy of the oral cavity and Verrucous Carcinoma (VC) is its least invasive form with no metastasis potential. Leukoplakia (clinical term for hyperkeratosis and acanthosis with and without dysplasia) is the most common pre-malignant lesion of the oral cavity. Human Papilloma Virus (HPV) has been recognized as an etiologic factor for mentioned lesions. In this study the relationship between high risk types of this virus (HPVHR) with VC and Leukoplakia is investigated. Materials and method. Forty-one paraffin-embedded blocks including 21 VC, 20 leukoplakias in addition to 18 normal oral mucosal tissues as the control group were studied by Polymerase Chain Reaction (PCR) to detect HPV 16, 18, 31 and 33. Results. In three specimens of VCs (14.3%) HPVHR was detected. Each of these contained both HPV 16 and 18. All three positive specimens belonged to women older than 65 and were obtained from the vestibule of the mandible. Neither Leukoplakia nor normal mucosa showed HPV presence. No significant relationship between HPV and VC was found compared with the control group (p = 0.23). Conclusion. This study did not show relationship between HPV and leukoplakia. Although no statistically significant relationship was found between HPV and VC, but considering sample size limitation for such uncommon cases, its presence in three cases of 14 makes more investigations to overcome the controversies necessary.

HPV genotype prevalence in cervical specimens with abnormal cytology: A report from north-east Italy

We have investigated the prevalence of HPV DNA in cervical samples collected from 1335 women with abnormal Pap test and analysed the degree of association of HPV genotype with cervical cytological abnormality and also with patient age. The study was principally aimed at providing some cross-sectional figures on the epidemiology of HPV in our area, where the ethnic background is expected to rapidly evolve due to extensive immigration from overseas. 471 (35.3%) of the 1335 patients screened were positive for HPV DNA. A clear association was observed between cytological findings and the proportion of patients with positive HPV PCR, namely 24.0% HPV positivity in the ASCUS group (atypical squamous cells of undetermined significance), 48.7% in LSIL group (low grade squamous intraepithelial lesions), and 71.9% in HSIL group (high grade squamous intraepithelial lesions) (p-value < 0.001). High-risk (HR) HPV prevalence appeared to be different from other areas of the world; we have detected a high prevalence rate of HPV-16, 31, and 58 and a low prevalence rate of HPV-18 and 11. The prevalence of both HR and low risk (LR) genotype groups was clearly related to age (p-value < 0.001), since the prevalence of LR group had a nadir between 41 and 50 y of age and 2 peaks at 15-20 y and at over 60 y, while the curve of prevalence of HR genotypes displayed an almost inverse trend.